FDA Adverse Event Database Study Grant Specifies 15 NMEs To Track
Executive Summary
Bristol-Myers Squibb's oral anti-diabetic Glucophage is one of 15 new molecular entities FDA would like to track through its fiscal 1999 cooperative grant program for use of pharmacoepidemiological databases linked to medical records, the agency said in a June 19 Federal Register notice announcing the $1.4 mil. program.